The growth rate of China's pharmaceutical export slowed down, only increased by 6.7% in the first three quarters

Rong Di, deputy director of the Western Medicine Department of the national medical insurance chamber of Commerce, said at the "China Pharmaceutical Export Information Research Conference" that China's pharmaceutical foreign trade is facing a difficult situation and the export growth continues to slow down In the first three quarters of this year, the overall growth rate of Pharmaceutical Foreign Trade was only 6.7%, lower than the average export level of the pharmaceutical industry Rongdi introduced four characteristics of China's Pharmaceutical Foreign Trade in the first three quarters in detail at the meeting: first, the overall growth rate slowed down, only reaching 6.7%, lower than the export level of the whole industry In the first three quarters, the lack of global economic growth momentum and weak demand in the international market did not fundamentally change, leading to a severe situation in the development of China's pharmaceutical foreign trade, and the contradiction of excess pharmaceutical production capacity is very prominent Second, the profit space is constantly compressed From the perspective of segmentation, in the first three quarters, the export profit margin of bulk APIs was generally lower than 7%, and even as low as 3-5% for individual varieties; the export profit margin of characteristic APIs fell sharply from the previous high of 40-50%; the export profit margin of domestic generic pharmaceutical enterprises was also low due to their small scale, and only 5% for the top 10 listed companies; the export profit margin of pharmaceutical excipients and consumables products The profit margin has declined from 40% in 2011 to 10% - 20% now; due to the restriction of EU regulations, the income of Chinese patent medicine exported to EU has plummeted, and the export profit margin has also been declining Third, structural problems are becoming more and more obvious Most of the drugs exported by our country are relatively low-end products such as APIs and disposable consumables, while the export of high-end varieties is not much Even for low-end products, the export performance is not optimistic For example, since the fourth quarter of 2012, the revenue of bulk API has experienced a continuous and substantial negative growth, and by the third quarter of this year, the year-on-year decline was 9.5% Fourth, the export of preparations showed a sustained growth momentum, but the growth was not significant In the first three quarters, the growth rate reached 7.63% year-on-year, which is still not ideal compared with the growth rate of 30% in the previous years; the export growth rate of Chinese patent medicine has a negative growth for the first time this year Rongdi said that under the restriction of many factors, such as not obvious economic recovery abroad and many contradictions at home, the export performance of China's pharmaceutical foreign trade will still be unsatisfactory in the short term, and the transformation and upgrading of enterprises is the long-term plan.